In addition to PD-L1 expression level, other disease parameters and biomarkers, such as tumor-infiltrating lymphocytes [74–76], tumor mutation burden [79–81], mismatch-repair deficiency [82], and gene expression profile [83] have been investigated to facilitate the prediction of response to ICB therapy. Here, CD274 is linked to neoplasm.